The article states that Abbott is prepared to provide about 50 to 70 percent of the market...The coated stent was considered the wave of the future until 2005 and 2006, when concerns about blood clots led to several recalls. But many of the questions revolved around the way the stents were inserted and complications from medication taken afterward to prevent clots, and not about the devices themselves....BD
The heart stent produced by 4,000 workers in Temecula at Abbott Laboratories' factory -- a product that many say could end up being the best of its kind -- could hit the American market within weeks.
Abbott expects the U.S. Food and Drug Administration to approve Xience V, its entry into the drug-coated stent market, sometime before July. That is likely to keep the Temecula plant and its 4,000 workers busy for years to come.
Based on a series of clinical trials, Abbott's drug-eluting stent could go straight to the head of the class. Tests, including one just concluded this month, indicate that Xience could eventually dominate the three competing medical device companies that make these products.